Elvitegravir

Type: Keyphrase
Name: Elvitegravir
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Health Tip: Enjoy Your Coffee, But ...

-- Coffee contains beneficial nutrients, but fattening sweeteners can dampen these benefits.The Academy of Nutrition and Dietetics offers this advice when it comes to drinking coffee:Beware of additives or "designer" coffee drinks.Opt for a fat-free milk ... [Published Drugs.com - Oct 17 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate

Paul E. Sax, MD, Andrew Zolopa, MD, Indira Brar, MD, Richard Elion, MD, Roberto Ortiz, MD, Frank Post, MD, PhD, FCP (SA), Hui Wang, PhD, Christian Callebaut, PhD, Hal Martin, MD, MPH, Marshall W. Fordyce, MD, Scott McCallister, MDDisclosure ... [Published General Medicine eJournal - Oct 13 2014]
First reported Oct 09 2014 - Updated Oct 10 2014 - 2 reports

VITEKTA (Elvitegravir) Tablet, Film Coated [Gilead Sciences, Inc.]

First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

STRIBILD (Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate) Tablet, Film Coated [State Of Florida DOH Central Pharmacy]

First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

STRIBILD (Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate) Tablet, Film Coated [State Of Florida DOH Central Pharmacy]

First reported Oct 03 2014 - Updated Oct 03 2014 - 2 reports

GILEAD SCIENCES : Investigational Tenofovir Alafenamide TAF-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies

By a News Reporter-Staff News Editor at AIDS Weekly -- Gilead Sciences, Inc. (Nasdaq:GILD) announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide ... [Published 4 Traders - Oct 03 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

FDA approves two new doses of elvitegravir, in addition to its current use in Stribild

Facebook Twitter Google + Email PrintOn September 24, 2014, the FDA approved two new standalone doses of the integrase inhibitor elvitegravir, which now comes with the brand name Vitekta. The 85mg dose can be taken with Reyataz (atazanavir) and Kaletra ... [Published Project Inform - Sep 30 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

New version of tenofovir appears to be safe and effective

Facebook Twitter Google + Email PrintOn September 24, 2014, early results were released from two 96-week clinical studies of a new form of tenofovir (TAF, or tenofovir alafenamide), compared to its currently available form (TDF, or tenofovir disoproxil ... [Published Project Inform - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 2 reports

New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ...

And if you're wondering what the big deal is, welcome to the club. In fact, the Canadians beat us to the punch with more significant approval, the co-formulated darunavir/cobicistat, branded as Prezcobix -- which sounds like one favorite British breakfast ... [Published The Body PRO - Sep 30 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 6 reports

Elvitegravir / Vitekta FDA Approval

On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ... [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 4 reports

Gilead's two phase 3 trials of investigational TAF-based single tablet HIV regimen meets primary objectives

Gilead Sciences, announced that two phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met ... [Published PharmaBiz - Sep 26 2014]
First reported Sep 24 2014 - Updated Sep 25 2014 - 8 reports

Single-Tablet HIV Regimen Shows Promise in Late-Stage Studies

Trials meet 48-week primary objectivesPositive results have been reported from two phase III clinical trials (Studies 104 and 111) evaluating an investigational once-daily single-tablet regimen containing tenofovir alafenamide (TAF, Gilead Sciences) for ... [Published PT Community - Sep 24 2014]

Quotes

The investigators concluded that "NPEP has been increasingly and repeatedly utilized, reflecting a subpopulation that may benefit from PrEP."
...As a result, the study authors concluded that "COBI [cobicistat] may be an option for patients with CrCl 50 to ≤ 70 mL/min."
...profile," said Norbert Bischofberger , PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences . "Based on these Phase 3 results, we believe that the E/C/F/TAF single tablet regimen has the potential to optimize HIV therapy for a wide range of treatment-naive patients."
"This is the first time we are developing a protease inhibitor-containing single-tablet regimen, and we're able to do that based on the small milligram size of GS 7340, which is less than one tenth of the amount of the 300 mg of tenofovir disoproxil fumarate contained in Viread and Truvada."

More Content

All (53) | News (43) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Health Tip: Enjoy Your Coffee, But ... [Published Drugs.com - Oct 17 2014]
Three Quarters of NPEP Users Show Interest in T... [Published National AIDS Treatment Advocacy Project - Oct 17 2014]
Cobicistat Safe for HIV-Positive Patients With ... [Published The Body PRO - Oct 15 2014]
Tenofovir Alafenamide vs. Tenofovir Disoproxil ... [Published General Medicine eJournal - Oct 13 2014]
FDA Fixes Position on NCE Exclusivity for Certa... [Published FDA Law Blog - Oct 13 2014]
VITEKTA (Elvitegravir) Tablet, Film Coated [Gil... [Published DailyMed Drug Label Updates for the last seven ... - Oct 10 2014]
STRIBILD (Elvitegravir, Cobicistat, Emtricitabi... [Published DailyMed Drug Label Updates for the last seven ... - Oct 10 2014]
VITEKTA (Elvitegravir) Tablet, Film Coated [Gil... [Published DailyMed Drug Label Updates for the last seven ... - Oct 09 2014]
Recent developments keep Gilead ahead of the pa... [Published European Pharmaceutical Review - Oct 08 2014]
STRIBILD (Elvitegravir, Cobicistat, Emtricitabi... [Published DailyMed Drug Label Updates for the last seven ... - Oct 07 2014]
GILEAD SCIENCES : Investigational Tenofovir Ala... [Published 4 Traders - Oct 03 2014]
The Importance Of TAF To Gilead [Published Seeking Alpha - Oct 03 2014]
FDA approves two new doses of elvitegravir, in ... [Published Project Inform - Sep 30 2014]
New version of tenofovir appears to be safe and... [Published Project Inform - Sep 30 2014]
New FDA HIV Drug Approvals Unlikely to Have Muc... [Published The Body PRO - Sep 30 2014]
New FDA HIV Drug Approvals Unlikely to Have Muc... [Published The Body - Sep 29 2014]
FDA approves new HIV drug booster cobicistat as... [Published Project Inform - Sep 29 2014]
CHMP Announces Positive Opinion for REZOLSTA(TM... [Published Scottrade - Sep 29 2014]
Elvitegravir / Vitekta FDA Approval [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
Gilead receives approval for two HIV-1 cocktail... [Published Drugtopics.com - Sep 26 2014]
FDA Approves Two Medications to Treat HIV Infec... [Published AIDSinfo At-a-Glance: Offering Information on H ... - Sep 26 2014]
Gilead's two phase 3 trials of investigational ... [Published PharmaBiz - Sep 26 2014]
FDA Approves Vitekta (elvitegravir) for HIV-1 I... [Published Drugs.com - Sep 26 2014]
FDA Approves 2 HIV-1 Cocktail Drugs [Published Diabetes Care - Sep 25 2014]
Gilead Scores with TAF-based HIV Regimen, Share... [Published Zacks.com - Sep 25 2014]
Gilead’s HIV Regimen Pulls Weight In Phase 3 St... [Published Bioresearch Online - Sep 25 2014]
Tybost (Cobicistat) and Vitekta (Elvitegravir) ... [Published The Body - Sep 25 2014]
Gilead's HIV Drug Shows Potential in Two Mid-St... [Published American Journal of Public Health - Sep 25 2014]
Gilead will file safer HIV combination before y... [Published PMLive - Sep 25 2014]
The Medicines Patent Pool Adds New Sub-Licensin... [Published WGNT - Sep 25 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA Fixes Position on NCE Exclusivity for Certa... [Published FDA Law Blog - Oct 13 2014]
By Kurt R. Karst –Last Friday morning (October 10th) something interesting popped up out of the blue on FDA’s “What’s New Related to Drugs” webpage: the final version of FDA’s “Guidance for Industry – New Chemical Entity Exclusivity Determinations for ...
VITEKTA (Elvitegravir) Tablet, Film Coated [Gil... [Published DailyMed Drug Label Updates for the last seven ... - Oct 10 2014]
Updated Date: Oct 9, 2014 EST ...
STRIBILD (Elvitegravir, Cobicistat, Emtricitabi... [Published DailyMed Drug Label Updates for the last seven ... - Oct 10 2014]
Updated Date: Oct 7, 2014 EST ...
VITEKTA (Elvitegravir) Tablet, Film Coated [Gil... [Published DailyMed Drug Label Updates for the last seven ... - Oct 09 2014]
Updated Date: Oct 9, 2014 EST ...
STRIBILD (Elvitegravir, Cobicistat, Emtricitabi... [Published DailyMed Drug Label Updates for the last seven ... - Oct 07 2014]
Updated Date: Oct 7, 2014 EST ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.